Futibatinib and durvalumab before bladder cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have muscle-invasive bladder cancer that has not spread to lymph nodes or other organs (stage II or IIIA).
- You cannot take cisplatin chemotherapy due to kidney problems, hearing loss, nerve damage, or other reasons, or you have refused it.
- Your tumor shows high levels of FGFR (a protein) based on a previous biopsy or new biopsy.
- You are healthy enough for surgery to remove your bladder and plan to have it done.
- You have not had immunotherapy for muscle-invasive bladder cancer before.
- Your kidneys, liver, and blood counts meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs before bladder removal surgery in people with muscle-invasive bladder cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of a targeted drug (HDAC inhibitor, given directly into the bladder) and an immunotherapy (Durvalumab, given through a vein) before bladder removal surgery. It's for people with muscle-invasive bladder cancer who cannot take the chemo drug cisplatin.
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery can improve outcomes for people with muscle-invasive bladder cancer. It aims to see if this combination is more effective than chemotherapy alone.
This trial tests two drugs, enfortumab vedotin and pembrolizumab, given before surgery to remove the bladder or ureter in people with advanced bladder or upper urinary tract cancer that has spread to lymph nodes or other organs. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.